Seeking Alpha

Trovagene leaps on urine-based cancer mutation test news

  • Shares of Trovagene (TROV +16.6%) soar as the company announces the availability of the first urine test for cancer mutation monitoring.
  • The cell-free BRAF test detects and monitors V600E BRAF mutation, replacing tissue sample-based monitoring which "has limited practicality for patient monitoring due to costs, tumor heterogeneity and potential complications from the biopsy process." (PR)
  • Aegis' Raghuram Selvaraju says the news marks "a significant milestone for the company and [is] a core component of the firm's strategy aimed at attaining profitability near-term."
Comments (1)
  • Wilgii@aol.com
    , contributor
    Comments (3) | Send Message
     
    Just a small time player with big expectations for TROV. Hopefully, this is the start of something biggg!
    2 Oct 2013, 04:19 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs